English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
TürkçeHere's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings
For the quarter ended December 2025, Royalty Pharma (RPRX) reported revenue of $874 million, up 17.8% over the same period last year. EPS came in at $1.46, compared to $1.15 in the year-ago quarter.
The reported revenue represents a surprise of +5.95% over the Zacks Consensus Estimate of $824.94 million. With the consensus EPS estimate being $1.33, the EPS surprise was +10.19%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise: $251 million versus $230.74 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.9% change. Portfolio Receipts- Royalty Receipts- Products- Tysabri: $65 million versus $64.05 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change. Portfolio Receipts- Royalty Receipts- Products- Imbruvica: $40 million compared to the $41.09 million average estimate based on two analysts. The reported number represents a change of -13% year over year. Portfolio Receipts- Royalty Receipts- Products- Xtandi: $53 million versus the two-analyst average estimate of $49.32 million. The reported number represents a year-over-year change of +15.2%. Portfolio Receipts- Royalty Receipts- Products- Promacta: $27 million versus $22.16 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -38.6% change. Portfolio Receipts- Royalty Receipts- Products- Tremfya: $56 million compared to the $57.66 million average estimate based on two analysts. The reported number represents a change of +43.6% year over year. Portfolio Receipts- Milestones and other contractual receipts: $18 million versus $11.4 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +38.5% change. Portfolio Receipts- Royalty Receipts- Products- Evrysdi: $64 million versus the two-analyst average estimate of $58.83 million. The reported number represents a year-over-year change of +14.3%. Portfolio Receipts- Royalty Receipts- Products- Trodelvy: $12 million versus $11.79 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change. Portfolio Receipts- Royalty Receipts- Products- Total: $856 million versus $813.54 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +17.4% change. Portfolio Receipts- Royalty Receipts- Products- Trelegy: $95 million versus the two-analyst average estimate of $93.7 million. The reported number represents a year-over-year change of +28.4%. Portfolio Receipts- Royalty Receipts- Products- Spinraza: $14 million versus the two-analyst average estimate of $13.37 million. The reported number represents a year-over-year change of -6.7%.View all Key Company Metrics for Royalty Pharma here>>>
Shares of Royalty Pharma have returned +9.5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Royalty Pharma PLC (RPRX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).